$VERX

Vertex, Inc. (VERX): Results of Operations and Financial Condition

Vertex, Inc. (VERX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 verx-20260803xex99d1.htm EX-99.1 ​ Exhibit 99.1 Vertex Announces Second Quarter 2026 Financial Results KING OF PRUSSIA, PA – August 3, 2026: Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, tod

Original reporting
Published Aug 3, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$VERX
Bullish
high confidence
Mentioned
$VERX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VERXBullishHigh
01

Why it matters

Traders can reprice the stock based on the disclosed guidance ranges and margin/EBITDA trajectory, while monitoring whether ARR growth and NRR stability persist into Q3.

02

Market read

A primary earnings-and-guidance disclosure with specific revenue and adjusted EBITDA ranges for Q3 and full-year 2026, plus improving adjusted EBITDA margin and ARR growth.

03

What to watch

The company notes it will not update outlook until next quarterly results, and forward-looking adjusted EBITDA is not reconciled to GAAP net income, leaving potential GAAP volatility risk.

Relevance 7/10Novelty 9/10Timing: after-hours filing and earnings release for Q2 2026, with Q3 and full-year guidance ranges.

Background

SEC 8-K Item 2.02 with Exhibit 99.1 covering Vertex’s Q2 2026 financial results, key operating metrics (ARR, NRR, GRR), and guidance for Q3 and full-year 2026.

Company-level read

Ticker impact

$VERXBullishHigh confidence
Context

Vertex reported Q2 2026 results and raised/narrowed outlook, including revenue $204.0M (+10.5% YoY) and Q3 adjusted EBITDA $55.0M-$57.0M.

Expected impact

Likely positive bias for the next session and into the Q3 print window, with focus on whether ARR, NRR, and cloud growth sustain.

Evidence & confidence

The filing discloses multiple forward-looking datapoints (Q3 revenue and adjusted EBITDA ranges, full-year revenue and adjusted EBITDA ranges) alongside improving operating metrics (adjusted EBITDA margin 25.0% vs 20.8% YoY).

Market effects

Signals continued demand for indirect tax and compliance software, with e-invoicing momentum and cloud growth supporting the SaaS-like revenue model.

Limited direct regional read-through; primarily a US-listed software/compliance name with global customer base.

Supports the broader theme of expanding global e-invoicing mandates increasing spend on compliance and transaction lifecycle software.

Counterpoint

Despite strong non-GAAP profitability, operating loss persists ($4.4M), and NRR is flat at 105%, so upside may be capped if retention or cloud growth decelerates.

Key entities

  • Vertex, Inc.

    Decision-to-Defense global indirect tax and compliance company reporting Q2 2026 results and issuing Q3 and full-year 2026 guidance.

  • Christopher Young

    CEO quoted on Q2 performance, AI-First strategy progress, and operating discipline.

  • John Schwab

    CFO quoted on narrowing revenue guidance range and raising adjusted EBITDA outlook.

Related articles

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.

$VERXMed

Vertex stock tumbles on cloud growth miss, price target cuts

Vertex Inc. (NASDAQ:VERX) shares dropped 13.2% after its Q2 results missed cloud growth expectations and analysts cut price targets. DA Davidson lowered its target to $12 from $15, citing slower cloud conversions and reduced FY26 cloud growth guidance to 18% from 25%. Other analysts also adjusted targets following guidance and deal-cycle comments.

$VERXMedAI 8/10

Vertex Announces Second Quarter 2026 Financial Results

Vertex, Inc. (NASDAQ: VERX) reported Q2 2026 results for the quarter ended June 30, 2026. Total revenue rose 10.5% to $204.0 million, with software subscription revenue up 10.7% to $174.8 million and cloud revenue up 17.9% to $101.7 million. Adjusted EBITDA increased to $51.0 million. Outlook: Q3 revenue $208.0-$211.0 million and adjusted EBITDA $55.0-$57.0 million; FY 2026 revenue $825.0-$830.0 million and adjusted EBITDA $206.0-$210.0 million.